Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of oral ASTX727 in lower-risk myelodysplastic syndromes
jRCT2080224585Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inqovi in myelodysplastic syndrome (MDS) (5 cohorts), sponsored by Otsuka Pharmaceutical Co., Ltd. Started Mar 2019; status: completed.
02
Drugs
inqovi
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2080224585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224585.